CN1989954A - Tartaric acid metoprolol sustained release capsules and its preparation method - Google Patents
Tartaric acid metoprolol sustained release capsules and its preparation method Download PDFInfo
- Publication number
- CN1989954A CN1989954A CN 200510136033 CN200510136033A CN1989954A CN 1989954 A CN1989954 A CN 1989954A CN 200510136033 CN200510136033 CN 200510136033 CN 200510136033 A CN200510136033 A CN 200510136033A CN 1989954 A CN1989954 A CN 1989954A
- Authority
- CN
- China
- Prior art keywords
- sustained release
- slow
- tartaric acid
- principal agent
- pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A tartaric acid metoprolol slow release capsules and its preparation. It is prepared by tartaric acid metoprolol, slow release materials and findings in the weight ratio of 25-100:5-20:131-165 to preparing slow-release pellets with different release degree, the slow release materials are one to four of acrylic resin, hydroxypropyl methyl cellulose, ethyl cellulose, phthalate vinegar acid cellulose and polyvinylpyrrolidone; the content of tartaric acid metoprolol in single capsules is 25-100mg. Preparation method uses rolling shaping pill mean. The capsule can maintain balanced and durable effective blood drug concentration in the same dosage and time intervals, or decreases dosage and side effects remaining same drug effect; In particular, it is dispersable agent, it not only can improve the contact area of gastrointestinal tract to making drug absorption completely and the bioavailability higher, and it can get ideal release drugs rate using different pellets combination. In addition, the craft of preparation method used is simple and easy to operating and controlling.
Description
Technical field
The present invention relates to medicine and preparation field thereof, particularly relate to a kind of hypertension, angina pectoris and hyperthyroid tartaric acid metoprolol sustained release capsules and preparation method thereof for the treatment of.
Background technology
Hypertension, angina pectoris and hyperthyroidism are commonly encountered diseases, frequently-occurring disease, and sickness rate is very high, if malpractice or untimely treatment just might cause severe complications and the physical and mental health that endangers the patient, even life danger occur.Spectinomycin hydrochloride is a kind of treatment hypertension, angina pectoris and hyperthyroid ancillary drug, be widely used in clinical treatment, especially it has been used as a line medicine of curing the hypertension composite reagent, but it is fairly obvious that its shortcoming is side effect, and untoward reaction mainly comprises the symptom of aspects such as cardiovascular system, central nervous system, digestive system and vision, audition.The spectinomycin hydrochloride that uses clinically is the fast-release tablet of 25mg/ sheet, 50mg/ sheet and 100mg/ sheet at present.Since this drug oral after 1.5 hours blood drug level promptly reach peak value, and the reduction of blood pressure and blood drug level are not parallel, so the patient need take 2 every day, will feel very inconvenient like this for middle-older patient and handicapped person.
Summary of the invention
In order to address the above problem, only need are oral once, lasting medicine is stablized, the high and cheap tartaric acid metoprolol sustained release capsules of bioavailability to the object of the present invention is to provide a kind of every day.
Another object of the present invention is to provide a kind of method for preparing tartaric acid metoprolol sustained release capsules.
In order to achieve the above object, tartaric acid metoprolol sustained release capsules provided by the invention mainly by as the spectinomycin hydrochloride of active component be coated on the active component skin and have the slow-release material of slow releasing function and acceptable accessories with 25～100: 5～20: 131～165 weight ratio is mixed with the slow-release micro-pill with different releases and combines, and slow-release material is that in acrylic resin, hydroxypropyl emthylcellulose, ethyl cellulose, cellulose acetate-phthalate and the polyvinylpyrrolidone any one is to four kinds; The content of simple grain capsule mesotartaric acid metoprolol is 25～100mg.
Described slow-release micro-pill mainly by as the hollow ball core of parent nucleus, be coated on the outer principal agent layer of ball core and be coated on the outer sustained release coating layer of principal agent layer and form.Hollow ball core is the blank basic ball that comprises basic ball and basic ball protective layer; The principal agent layer is made up of spectinomycin hydrochloride and adjuvant, and its outer surface is surrounded by layer protective layer.
Described protective layer and adjuvant are the hydrophilic colloid that is selected from sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, sodium alginate and arabic gum; Be selected from the oil infiltration agent of polysiloxanes, dimethyl siloxane; Be selected from a kind of in lactose, starch, sucrose, polylactic acid, polyethylene, polypropylene, polyvinyl alcohol, triethyl citrate, ethanol, silica gel and talcous other material to three kinds.
The preparation method of tartaric acid metoprolol sustained release capsules provided by the invention adopts and rolls into the ball method, comprises step 1: at first commercially available hollow ball core is placed the CF comminutor, injection concentration is 50% sucrose syrup, up to the abundant moistening of hollow ball core; Step 2: will be behind spectinomycin hydrochloride and the adjuvant powder mix homogeneously add and handled 20～60 minutes in the above-mentioned comminutor and obtain ganoid principal agent grain, after finishing, principal agent grain parcel continues to spray 50% sucrose syrup, and adding protective layer adjuvant carries out principal agent protective layer parcel, principal agent grain after will wrapping up then places 25～80 ℃ vacuum drying oven inner drying 3～8 hours, or 50～80 ℃ common electrical drying baker inner drying 6～10 hours; Step 3: with 95% an amount of ethanol or water dissolution slow-release material, in addition coating is added in the 95% an amount of ethanol with adjuvant 2～5g simultaneously, and supersound process 8～15 minutes, under stirring state, this suspension is joined mix homogeneously in the above-mentioned slow-release material alcoholic solution then and make sustained release coating liquid; Step 4: the spectinomycin hydrochloride principal agent grain that drying is good is reentered in the comminutor, the sustained release coating liquid that even injection has prepared carries out Cotton seeds, when sustained release coating liquid be consumed to its total amount 1/2～2/3 the time, stop coating, 1/3 principal agent grain conduct in the taking-up grain-making machine is slow-release micro-pill in short-term, remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Or when sustained release coating liquid be consumed to its total amount 1/2～2/3 the time, stop coating, 1/5 principal agent grain conduct in the taking-up comminutor is slow-release micro-pill in short-term, continuing coating to sustained release coating liquid is consumed to 2/3 of its total amount～4/5 and o'clock stops coating, slow-release micro-pill when taking out in the principal agent grain conduct that accounts for total dose 2/5 in the comminutor, remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Step 5: will be in short-term, when middle and the long time slow-release micro-pill place 25～80 ℃ vacuum drying oven inner drying 1～3 hour respectively, or 50～80 ℃ common electrical drying baker inner drying 3～6 hours; Step 6: measure respectively in short-term, when middle and the content and the dissolution of long time slow-release micro-pill, and calculate separately addition according to this, the hard capsule of packing into and being made by common osseocolla material after at last several micropills being mixed in proportion detects and promptly makes tartaric acid metoprolol sustained release capsules of the present invention after qualified.Inlet temperature during coating is controlled at 20～50 ℃.
Tartaric acid metoprolol sustained release capsules provided by the invention can overcome takes blood drug level peak, the paddy phenomenon that occurs behind the common quick release sheet, can keep balance, persistent effective blood drug concentration in equal dosage and interval, thereby increase curative effect; Or reduce dosage when keeping equal drug effect, take the side effect that medicine brings to the patient thereby reduce; Particularly because it belongs to the decentralized preparation, this not only can improve medicine and gastrointestinal contact area, makes drug absorption complete, thereby the bioavailability height, and the micropill that can utilize several different rate of releasing drug makes up and obtains ideal rate of releasing drug, keeps long action time.In addition, preparation method technology of the present invention is simple, is easy to operate and control, thereby can greatly shortens the processing time.
Description of drawings
Below in conjunction with the drawings and specific embodiments tartaric acid metoprolol sustained release capsules provided by the invention and preparation method thereof is elaborated.
Fig. 1 is a tartaric acid metoprolol sustained release capsules preparation method flow chart.
The specific embodiment
Embodiment 1
With 1000 tartaric acid metoprolol sustained release capsules is benchmark, and the commercially available hollow ball core of 105g between 25～30 orders placed the CF300 comminutor, and injection concentration is 50% sucrose syrup, up to the abundant moistening of hollow ball core; 25g crossed to add behind the starch powder mix homogeneously that the spectinomycin hydrochloride of 100 mesh sieves and lactose that 20g crosses 80 mesh sieves and 20g cross 100 mesh sieves handled 50 minutes in the above-mentioned comminutor and obtain ganoid principal agent grain, after finishing, principal agent grain parcel continues to spray 50% sucrose syrup, and the starch that adds 8g carries out principal agent protective layer parcel, principal agent grain after will wrapping up then places 80 ℃ vacuum drying oven inner drying 3 hours, or 80 ℃ common electrical drying baker inner drying 6 hours; With 95% an amount of dissolve with ethanol 10g crylic acid resin slow-release material EUDRAGIT RS100, in addition coating is added in the 95% an amount of ethanol with adjuvant Pulvis Talci 3g simultaneously, and supersound process 10 minutes, under stirring state, this suspension is joined mix homogeneously in the above-mentioned EUDRAGIT RS100 alcoholic solution then and make sustained release coating liquid; The spectinomycin hydrochloride principal agent grain that drying is good is reentered in the comminutor, the sustained release coating liquid that even injection has prepared carries out Cotton seeds, when sustained release coating liquid be consumed to its total amount 2/3 the time, stop coating, 1/3 principal agent grain conduct in the taking-up grain-making machine is slow-release micro-pill in short-term, remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Or when sustained release coating liquid be consumed to its total amount 1/2 the time, 1/5 principal agent grain conduct in the taking-up comminutor is slow-release micro-pill in short-term, continue coating to sustained release coating liquid and be consumed to 4/5 o'clock of its total amount and stop coating, take out the principal agent grain that accounts for total dose 2/5 in the comminutor as in the time slow-release micro-pill; Remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Will be in short-term, when middle and the long time slow-release micro-pill placed 60 ℃ of vacuum drying oven inner dryings respectively 2 hours, or 60 ℃ of common electrical drying baker inner dryings 4 hours; Measure respectively in short-term, when middle and the content and the dissolution of long time slow-release micro-pill, and calculate separately addition according to this, 1000 hard capsules of being made by common osseocolla material of packing into after at last several slow-release micro-pill being mixed in proportion detect and promptly make tartaric acid metoprolol sustained release capsules provided by the invention after qualified.
Embodiment 2
With 1000 tartaric acid metoprolol sustained release capsules is benchmark, and the commercially available hollow ball core of 105g between 25～30 orders placed the CF300 comminutor, and injection concentration is 50% sucrose syrup, up to the abundant moistening of hollow ball core; 50g is crossed pregelatinized Starch powder mixes that the spectinomycin hydrochloride of 100 mesh sieves and polyethylene glycol 6000 that 15g crosses 80 mesh sieves and 13g cross 100 mesh sieves evenly to add and handled 50 minutes and obtained ganoid principal agent grain in the above-mentioned comminutor in the back, after finishing, principal agent grain parcel continues to spray 50% sucrose syrup, and the starch that adds 5g carries out principal agent protective layer parcel, principal agent grain after will wrapping up then places 80 ℃ vacuum drying oven inner drying 3 hours, or 80 ℃ common electrical drying baker inner drying 6 hours; Respectively with the polyvinylpyrrolidone of 95% an amount of dissolve with ethanol 8g with the hydroxypropyl emthylcellulose of the water dissolution 12g of 5mL, in addition coating is added in the 95% an amount of ethanol with adjuvant Pulvis Talci 3g simultaneously, and supersound process 10 minutes, under stirring state, this suspension is joined mix homogeneously in the above-mentioned slow-release material alcoholic solution then and make sustained release coating liquid; The spectinomycin hydrochloride principal agent grain that drying is good is reentered in the comminutor, the sustained release coating liquid that even injection has prepared carries out Cotton seeds, when sustained release coating liquid be consumed to its total amount 2/3 the time, stop coating, 1/3 principal agent grain conduct in the taking-up grain-making machine is slow-release micro-pill in short-term, remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Or when sustained release coating liquid be consumed to its total amount 1/2 the time, 1/5 principal agent grain conduct in the taking-up comminutor is slow-release micro-pill in short-term, continue coating to sustained release coating liquid and be consumed to 4/5 o'clock of its total amount and stop coating, take out the principal agent grain that accounts for total dose 2/5 in the comminutor as in the time slow-release micro-pill; Remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Will be in short-term, when middle and the long time slow-release micro-pill placed 60 ℃ of vacuum drying oven inner dryings respectively 2 hours, or 60 ℃ of common electrical drying baker inner dryings 4 hours; Measure respectively in short-term, when middle and the content and the dissolution of long time slow-release micro-pill, and calculate separately addition according to this, 1000 hard capsules of being made by common osseocolla material of packing into after at last several slow-release micro-pill being mixed in proportion detect and promptly make tartaric acid metoprolol sustained release capsules provided by the invention after qualified.
Claims (8)
1, a kind of tartaric acid metoprolol sustained release capsules, it is characterized in that: described tartaric acid metoprolol sustained release capsules mainly by as the spectinomycin hydrochloride of active component be coated on the active component skin and have the slow-release material of slow releasing function and acceptable accessories with 25～100: 5～20: 131～165 weight ratio is mixed with the slow-release micro-pill with different releases and combines, and slow-release material is that in acrylic resin, hydroxypropyl emthylcellulose, ethyl cellulose, cellulose acetate-phthalate and the polyvinylpyrrolidone any one is to four kinds; The content of simple grain capsule mesotartaric acid metoprolol is 25～100mg.
2, tartaric acid metoprolol sustained release capsules according to claim 1 is characterized in that: described slow-release micro-pill mainly by as the hollow ball core of parent nucleus, be coated on the outer principal agent layer of ball core and be coated on the outer sustained release coating layer of principal agent layer and form.
3, tartaric acid metoprolol sustained release capsules according to claim 2 is characterized in that: described hollow ball core is the blank basic ball that comprises basic ball and basic ball protective layer.
4, tartaric acid metoprolol sustained release capsules according to claim 2 is characterized in that: described principal agent layer is made up of spectinomycin hydrochloride and adjuvant, and its outer surface is surrounded by layer protective layer.
5, according to the tartaric acid metoprolol sustained release capsules described in claim 1 or 4, it is characterized in that: described protective layer and adjuvant are the hydrophilic colloid that is selected from sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, sodium alginate and arabic gum; Be selected from the oil infiltration agent of polysiloxanes, dimethyl siloxane; Be selected from a kind of in lactose, starch, sucrose, polylactic acid, polyethylene, polypropylene, polyvinyl alcohol, triethyl citrate, ethanol, silica gel and talcous other material to three kinds.
6, tartaric acid metoprolol sustained release capsules according to claim 1 is characterized in that: the optimum content of described simple grain capsule mesotartaric acid metoprolol is 1.5mg.
7, a kind of preparation method of tartaric acid metoprolol sustained release capsules as claimed in claim 1, it is characterized in that: the preparation method of described tartaric acid metoprolol sustained release capsules adopts the ball method of rolling into, comprise step 1: at first commercially available hollow ball core is placed the CF comminutor, injection concentration is 50% sucrose syrup, up to the abundant moistening of hollow ball core; Step 2: will be behind spectinomycin hydrochloride and the adjuvant powder mix homogeneously add and handled 20～60 minutes in the above-mentioned comminutor and obtain ganoid principal agent grain, after finishing, principal agent grain parcel continues to spray 50% sucrose syrup, and adding protective layer adjuvant carries out principal agent protective layer parcel, principal agent grain after will wrapping up then places 25～80 ℃ vacuum drying oven inner drying 3～8 hours, or 50～80 ℃ common electrical drying baker inner drying 6～10 hours; Step 3: with 95% an amount of ethanol or water dissolution slow-release material, in addition coating is added in the 95% an amount of ethanol with adjuvant 2～5g simultaneously, and supersound process 8～15 minutes, under stirring state, this suspension is joined mix homogeneously in the above-mentioned slow-release material alcoholic solution then and make sustained release coating liquid; Step 4: the spectinomycin hydrochloride principal agent grain that drying is good is reentered in the comminutor, the sustained release coating liquid that even injection has prepared carries out Cotton seeds, when sustained release coating liquid be consumed to its total amount 1/2～2/3 the time, stop coating, the 1/3 principal agent grain conduct in the taking-up grain-making machine is slow-release micro-pill in short-term; Remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Or when sustained release coating liquid be consumed to its total amount 1/2～2/3 the time, stop coating, take out in the comminutor 1/5 principal agent grain as slow-release micro-pill in short-term, continue coating to sustained release coating liquid and be consumed to 2/3 of its total amount～4/5 and o'clock stop coating, take out the principal agent grain that accounts for total dose 2/5 in the comminutor as in the time slow-release micro-pill; Remaining spectinomycin hydrochloride principal agent grain in the comminutor is proceeded sustained release coating handle, make the long time slow-release micro-pill up to having sprayed whole sustained release coating liquid; Step 5: will be in short-term, when middle and the long time slow-release micro-pill place 25～80 ℃ vacuum drying oven inner drying 1～3 hour respectively, or 50～80 ℃ common electrical drying baker inner drying 3～6 hours; Step 6: measure respectively in short-term, when middle and the content and the dissolution of long time slow-release micro-pill, and calculate separately addition according to this, the hard capsule of packing into and being made by common osseocolla material after at last several micropills being mixed in proportion detects and promptly makes tartaric acid metoprolol sustained release capsules of the present invention after qualified.
8, the preparation method of tartaric acid metoprolol sustained release capsules according to claim 7 is characterized in that: the inlet temperature during coating is controlled at 20～50 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510136033 CN1989954A (en) | 2005-12-29 | 2005-12-29 | Tartaric acid metoprolol sustained release capsules and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510136033 CN1989954A (en) | 2005-12-29 | 2005-12-29 | Tartaric acid metoprolol sustained release capsules and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1989954A true CN1989954A (en) | 2007-07-04 |
Family
ID=38212639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510136033 Pending CN1989954A (en) | 2005-12-29 | 2005-12-29 | Tartaric acid metoprolol sustained release capsules and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1989954A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732248B (en) * | 2010-01-20 | 2011-08-17 | 白求恩医科大学制药厂 | Metoprolol tartrate injection and preparation method thereof |
| CN102274205A (en) * | 2011-07-21 | 2011-12-14 | 佛山市隆信医药科技有限公司 | Metoprolol succinate sustained-release capsule and preparation method |
| CN102552163A (en) * | 2012-01-05 | 2012-07-11 | 金陵药业股份有限公司 | Metoprolol tartrate sustained release pellet and preparation method thereof |
| CN112999195A (en) * | 2021-02-26 | 2021-06-22 | 山东大学第二医院 | Etoricoxib sustained-release capsule and preparation method thereof |
-
2005
- 2005-12-29 CN CN 200510136033 patent/CN1989954A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732248B (en) * | 2010-01-20 | 2011-08-17 | 白求恩医科大学制药厂 | Metoprolol tartrate injection and preparation method thereof |
| CN102274205A (en) * | 2011-07-21 | 2011-12-14 | 佛山市隆信医药科技有限公司 | Metoprolol succinate sustained-release capsule and preparation method |
| CN102274205B (en) * | 2011-07-21 | 2013-03-13 | 佛山市隆信医药科技有限公司 | Metoprolol succinate sustained-release capsule and preparation method |
| CN102552163A (en) * | 2012-01-05 | 2012-07-11 | 金陵药业股份有限公司 | Metoprolol tartrate sustained release pellet and preparation method thereof |
| CN102552163B (en) * | 2012-01-05 | 2013-12-04 | 金陵药业股份有限公司 | Metoprolol tartrate sustained release pellet and preparation method thereof |
| CN112999195A (en) * | 2021-02-26 | 2021-06-22 | 山东大学第二医院 | Etoricoxib sustained-release capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101563390B1 (en) | Novel composition based on gamma-hydroxybutyric acid | |
| CN103006612B (en) | Lisinopril controlled-release tablet and preparation method thereof | |
| WO2014040548A1 (en) | Metoprolol sustained-release drug and preparation method therefor | |
| CN104814923B (en) | A kind of tamsulosin hydrochloride sustained release preparation and preparation method thereof and its application | |
| CN1989954A (en) | Tartaric acid metoprolol sustained release capsules and its preparation method | |
| CN102048701A (en) | Pitavastatin calcium enteric sustained-release micropill preparation and preparation method thereof | |
| CN103520129B (en) | Montelukast sodium pulse release preparation | |
| CN101874783A (en) | Sustained-release preparation containing melatonin and preparation method thereof | |
| CN101120931A (en) | Bezafibrate sustained-release composition | |
| AU2009315449B2 (en) | Novel method for preparing granulates of active principles, and granulates obtained thereof | |
| CN1631395A (en) | Gingko leaf sustained release formulation and preparation process thereof | |
| CN102319225A (en) | Trimetazidine hydrochloride sustained release tablet and preparation method thereof | |
| CN102895211A (en) | Sudden death and hypertension resistant metoprolol intelligent medicine release system and its preparation method | |
| CN102247366A (en) | Medicinal composition comprising quick-release pellets containing Enalapril or Enalapril-acid addition salt and slow-release pellets containing Felodipine | |
| CN102188388B (en) | Diclofenac sodium sustained-release pellet preparation and preparation method thereof | |
| CN1175812C (en) | Slow-released indapamide capsule and its prepn process | |
| CN1562009A (en) | Amlodipine benzenesulfonate slow-releasing capsule and its preparing method | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN101658507B (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation | |
| CN100569232C (en) | Sustained release medicament of compound gossypol acetate | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN101507713A (en) | High bioavailability proton pump inhibitor sustained-release technique | |
| CN101683340A (en) | Sustained-release preparation of compound metformin hydrochloride rosiglitazone and preparation method thereof | |
| CN101756981A (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| CN1985819A (en) | Slow released preparation containing metformin hydrochloride and gliclazide and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070704 |